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HEART MATTERS 
The use of novel anticoagulants 
in non-valvular atrial fibrillation 
Atrial Fibrillation (AF) occurs in 1-2% of the general population, 
making it the commonest sustained 
cardiac arrhythmia. It becomes more 
common as one gets older, with a 
prevalence of 5-15% at 80 years of 
age. Atrial fibrillation is independently 
associated with doubling of mortality, 
mostly associated with a higher risk of 
stroke. One-fifth of strokes are due to 
AF, with a proportion of 'cryptogenic' 
also likely to have undiagnosed AF as 
a cause. Anti-thrombotic therapy is the 
only treatment which reduces deaths in 
patients with AF. l 
The increased risk of stroke is 
present in all patients with AF, and no 
difference exists between patients 
with paroxysmal or permanent AF. 
However, numerous risk factors are 
independently related to an increased 
risk of thrombo-embolic disease. These 
risk factors include previous strokes! 
transient ischaemic attacks! thrombo-
embolic episodes, age, diabetes, 
hypertension, congestive heart failure, 
structural heart disease, and gender. 
Risk-stratification tools, notably 
CHADS2 and CHAPS2 -VASc scores 
(Table 1), have been created in order to 
better score and quantify the adjusted 
stroke rate for a given patient. A 
CHAPS2 -VASc score of 2 would confer 
a 2.2% yearly adjusted risk of stroke, 
while with a score of 6 the risk would 
go up to 9.8%.1.2 
Over 2 decades ago, numerous 
large multi-centre trials have shown 
that Vitamin-K Antagonists (VKA) 
significantly reduce the risk of stroke 
when compared to placebo with a 
relative risk (RR) reduction of 64%.3 
The anti-coagulant effect of VKAs is 
mediated by blocking the production 
of Vitamin K-dependent coagulation 
factors II, VII, IX and X. Starting a 
patient on anti-coagulation therapy, 
however, is not without risks. The 
increased risk of bleeding, especially 
gastro-intestinal and cerebral bleeds, 
are dreaded complications. A balance 
between the patient's risk of stroke and 
his/her risk of bleeding has also to be 
taken into consideration.1.3 
Studies comparing thrombo-
embolic prophylaxis with aspirin versus 
VKA all showed significant superiority 
of the latter. In fact, the efficacy of 
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aspirin in preventing stroke in AF is 
doubtful, as many studies comparing it 
to placebo failed to show a significant 
reduction of stroke. The few studies 
which showed a positive outcome for 
aspirin had their methodology heavily 
criticised. Notwithstanding, aspirin is 
still considered by some as an option 
in AF patients with no or a single stroke 
risk factor. I 
Thrombo-embolic prophylaxis with 
VKA, with warfarin being the most 
common, has been at the forefront in 
the management of AF patients. VKA 
therapy is fraught with many problems, 
mainly related to inter- and intra-patient 
variation in their pharmacological effect. 
The anti-coagulation effect of VKAs, 
measured using INR, is dependent 
on a patient's genetic makeup and 
associated with significant drug, 
alcohol and food interactions. Patients 
therefore cannot be given a 'standard 
dose' and need to get frequent INR 
testing, with the dose being adjusted 
accordingly. In 'real-life' Situations, over 
half of the time, patient on VKA are 
under-coagulated, and therefore are not 
getting the intended therapeutic benefit. 
Table 1: CH~DS2-VASc score adapted from the European Society of Cardiology guidelines for the management of Afl 
Risk factor-based approach expressed as a point based scoring Adjusted stroke rate according to 
system, with the acronym CHApSz-VASc (Note: maximum score is CHApSz-VASc score 9 since age may contribute 0, 1, or 2 points) 
Risk Factor Score CHAPS2- Patients Adjusted stroke VASc score (n=7329) rate (%/year) 
Conaestive heart failure/Left Ventricular dysfunction 1 0 1 0% 
Hypertension 1 1 422 1.3% 
Age >75 2 2 1230 2.2% 
Diabetes mellitus 1 3 1730 3.2% 
$trokeifIAlthrombo-embolism 2 4 1718 4.0% 
Vascular disease 1 5 1159 6.7% 
Age 65-74 1 6 679 9.8% 
Sex cateaorv (Le. female sex) 1 7 294 9.6% 
Maximum score 9 8 82 6.7% 
9 14 15.2% 
Many patients who, despite being 
on VKA therapy, develop thrombo-
embolic episodes are in fact found 
to be inadequately anti-coagulated. 
Warfarin and other VKAs also have 
a long half-life and therefore pose a 
problem when emergency surgery is 
needed. ' 
Novel Oral Anti-Coagulants 
(NOACs) have recently become 
available, as a 'non-VKA' alternative, 
for thrombo-embolic prophylaxis 
in non-valvular AF patients. ~ ,5 What 
these drugs share in common is 
that they block a single step in the 
coagulation cascade. Three drugs are 
currently approved by the European 
commission for the prevention of 
stroke in patients with non-valvular 
AF: the direct thrombin-inhibitor 
dabigatran (Pradaxae, Boehringer 
Ingelheim), and the direct factor 
Xa inhibitors rivaroxaban (Xareltoe, 
Bayer) and apixaban (Eliquise, Pfizerl 
Bristol-Myers Squibb). These 3 
NOACs have been accepted as an 
alternative to VKAs on the strength 
of the results obtained in 3 clinical 
trials comparing them to warfarin. 
The RE-LY trial compared 2 different 
dabigatran doses (1 1 Omg and 
1S0mg twice daily) to warfarin, the 
ROCKET·AF trial compared warfarin 
to rivaroxaban 20mg once daily, 
while ARISTOTLE compared warfarin 
to apixaban Smg twice daily. These 
trials followed earlier trials which 
had shown success for NOACs in 
preventing venous thrombo-embolic 
events (VTE) in patients undergoing 
orthopaedic surgery. 
The RE-LY trial was an open-
label trial comparing dose-adjusted 
warfarin to a randomised dose 
of either 11 Omg or 150mg of 
dabigatran.6 ln this trial, dabigatran 
1S0mg was superior to warfarin 
for the occurrence of stroke and 
systemic embolism, with no 
significant difference in major 
bleeding. Dabigatran 11 Omg was 
on the other hand non-inferior to 
warfarin , but with 20% fewer major 
bleeds. Rates of haemorrhagic stroke 
and intracranial haemorrhage were 
lower with both doses of dabigatran, 
but gastrointestinal bleeding was 
significantly increased with the 1S0mg 
dose. There was a non-significant 
numerical increase (28%) in myocardial 
infarction (MI) with both dabigatran 
doses. A meta-analysis of 7 dabigatran 
trials (including VTE prophylaxis trials) 
was carried out because of the concern 
of the small increase in myocardial 
infarctions.? Despite a 33% significant 
increase in MI , an 11 % reduction in 
all-cause mortality was seen when 
compared to warfarin. The increased 
risk of MI with dabigatran is thought 
to be due to the protective effect of 
warfarin, rather than being caused by 
the new direct thrombin inhibitor.s 
Rivaroxaban was approved for the 
prevention of stroke in non-valvular 
AF following the randomised double 
blinded ROCKET-AF trial.9This study 
showed that rivaroxaban 20mg once 
daily (reduced to 15mg in patients 
with renal failure) was non-inferior to 
warfarin, on an intention-to-treat basis, 
for the primary end-point of stroke and 
embolic episodes. Although the rates 
of mortality and ischaemic strokes were 
similar, patients on rivaroxaban had 
significantly less haemorrhagic strokes 
and intracranial haemorrhages. 
The latest drug approved for anti-
coagulation in non-valvular AF is 
apixaban, which was approved on the 
strength of the ARISTOTLE trial.10 In this 
study Smg twice daily apixaban (with 
dose reduction to 2.Smg in renal failure, 
> 80yrs, or < 60kg) was compared to 
warfarin in a randomized, double-blind, 
double-dummy manner. Apixaban 
showed superiority to warfarin with a 
21 % reduction in stroke and systemic 
embolism, a 31 % reduction in major 
bleeding, and an 11 % reduction in all-
cause mortality. 
The lack of head-to-head trials 
between different NOACs makes 
it inappropriate to make direct 
comparisons. The 3 major trials had 
different populations, with slightly 
different inclusion and exclusion 
criteria resulting in different baseline 
characteristics. For example, the 
ROCKET-AF trial had an older 
population with a higher CHADSz score 
than the other 2 trials. All drugs have 
some renal excretion (with 80% in 
dabigatran) and therefore all NOACs 
need to have their dosage reduced 
in renal failure. To date, there is no 
specific antidote to reverse their 
anticoagulant effects in case of 
emergencies; however they all have 
short half-lives. From a compliance 
point of view, rivaroxaban has the 
distinct advantage of being a once 
daily dose. As time goes by, NOACs 
will also find new indications, as 
seen by the recent EMA approval 
of rivaroxaban for acute coronary 
syndromes. 
The recent launch of oral non-
Vitamin K anticoagulants heralds a 
new era in stroke prophylaxis of non-
valvular AF patients. In the next few 
years they will surely replace warfarin 
which, despite its effectiveness, is 
frowned upon for its cumbersome 
dosing regimen by both patients and 
clinicians. S 
"'~ 1. Camm AI, KirclYlof P, Up GV et al. 
Gu~i1es lor the management of atrial 
~brillation. eLMopean Keart Joomal. 
2010;31 :2369-429. 
2. lip GV, Nieuwlaat A, Pisters A, Lane DA, 
Crf,-.s HJ. Aefining clinicaf fisk stratification 
for prOO"lCIing stroke and thromboembofism 
in atrial fibrillation U"Sing a novel risk factor· 
based approach: the eufO heart SOf'Iey on 
atrial fibri llation. Chest. 2010;137(2):263·72. 
3. Hart AG, Pearce LA, Aguilar MI. Meta· 
analysis: antitfvomboti: therajly to prevent 
stroke in patients who have norwafvular 
atrial fibri llation. Ann Intem Moo. 
2007:146:857-67. 
4. Gamm AI, Up GV. De Caterina A et at 
2012 focused update of the ESC Guidelines 
for the management of atrial ftbnllatioo. 
European Heart Journal. 2012;33:2719-47. 
5. Heidbuchel H. Vemamme P, Al ings M et 
al. European Keart Atlythm Association 
Practical Guide on the use of new oral 
anticoagulants in patients w~h non·vaMJlar 
atrial fibri llation. E~.2013;15:62Hl . 
6. ConnoUy SJ, E~ekownz MD, Yusuf S 
et al, ; AE·LY Steering Corrtnittee arid 
IJI\Iestigators. Dabigatran '0'5. warfarin in 
pane'lts with atrial f ibrillato:;>n. N Engl J Med 
2009;361:1139-11 51. 
7. lIdtino K, Kemandel: AV. Dabogatran 
association wfth higher fisk of acl.lle 
coronary ev<lI1ts: meta-arwlysis of 
noninferio<fty randomized controUed trials. 
Ardllntem Med. 2012;172:397-402. 
8. lip GV, lane DA. Does warfam for stmi<e 
t~is protect against MI 
in atrial fibrillation patients? Am J Med. 
2010;123:785-9. 
9. Pat~ MR, Mahaffey 'tW, Garg J et al. ; 
ROCKET AF IJI\Iestigators. Aivaroxaban vs. 
warfarin in nonvaM.dar atrial fibrillation . N 
Eng l J Med. 2011 :365:88Hl. 
10. Gfanger ce, Mexander JH. McM<JmIY 
JJ eI a1.; ARISTOTLE Corrvnittees arid 
IJI\Iestigators. Ap<xaban '0'5. wanam in 
patlef1ts with atrial f ibrillato:;>n. N Engl J Med. 
2011 ;365:981-92. 
